Novo Nordisk A/S
13.4.2026 12:35:57 CEST | Globenewswire | Press release
Novo Nordisk A/S - share repurchase programme
Novo Nordisk A/S - share repurchase programme
Bagsværd, Denmark, 13 April 2026 – On 4 February 2026, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Council of 16 April 2014 (MAR) and the Commission Delegated Regulation (EU) 2016/1052 of 8 March 2016 (the "Safe Harbour Rules"). This programme is part of the overall share repurchase programme of up to DKK 15 billion to be executed during a 12-month period beginning 4 February 2026.
Under the programme initiated 4 February 2026, Novo Nordisk will repurchase B shares for an amount up to DKK 3.8 billion in the period from 4 February 2026 to 4 May 2026.
Since the announcement 7 April 2026, the following transactions have been made:
| Number of B shares | Average purchase price | Transaction value, DKK | |
| Accumulated, last announcement | 9,967,992 | 2,586,404,548 | |
| 7 April 2026 | 260,000 | 235.50 | 61,229,022 |
| 8 April 2026 | 260,000 | 242.28 | 62,993,029 |
| 9 April 2026 | 260,000 | 236.25 | 61,424,153 |
| 10 April 2026 | 260,000 | 242.79 | 63,126,047 |
| Accumulated under the programme | 11,007,992 | 2,835,176,799 |
The details for each transaction made under the share repurchase programme are published on novonordisk.com.
With the transactions stated above, Novo Nordisk owns a total of 28,397,791 B shares of DKK 0.10 as treasury shares, corresponding to 0.6% of the share capital. The total amount of A and B shares in the company is 4,465,000,000 including treasury shares.
Novo Nordisk expects to repurchase B shares for an amount up to DKK 15 billion during a 12-month period beginning 4 February 2026. As of 10 April 2026, Novo Nordisk has since 4 February 2026 repurchased a total 11,007,992 B shares at an average share price of DKK 257.56 per B share equal to a transaction value of DKK 2,835,176,799.
Novo Nordisk is a leading global healthcare company founded in 1923 and headquartered in Denmark. Our purpose is to drive change to defeat serious chronic diseases built upon our heritage in diabetes. We do so by pioneering scientific breakthroughs, expanding access to our medicines and working to prevent and ultimately cure disease. Novo Nordisk employs about 68,800 people in 80 countries and markets its products in around 170 countries. Novo Nordisk's B shares are listed on Nasdaq Copenhagen (Novo-B). Its ADRs are listed on the New York Stock Exchange (NVO). For more information, visit novonordisk.com, Facebook, Instagram, X, LinkedIn and YouTube.
Contacts for further information
| Media: | |
| Ambre James-Brown +45 3079 9289 globalmedia@novonordisk.com | Liz Skrbkova (US) +1 609 917 0632 lzsk@novonordisk.com |
| Investors: | |
| Michael Novod +45 3075 6050 nvno@novonordisk.com | Jacob Martin Wiborg Rode +45 3075 5956 jrde@novonordisk.com |
| Max Ung +45 3077 6414 mxun@novonordisk.com | Sina Meyer +45 3079 6656 azey@novonordisk.com |
| Alex Bruce +45 34 44 26 13 axeu@novonordisk.com | Christoffer Sho Togo Tullin +45 3079 1471 cftu@novonordisk.com |
| Frederik Taylor Pitter +1 609 613 0568 fptr@novonordisk.com | Mads Berner Bruun +45 3075 2936 mbbz@novonordisk.com |
Company announcement No 25 / 2026
Attachments
Subscribe to releases from Globenewswire
Subscribe to all the latest releases from Globenewswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Globenewswire
Vislink LTD17.8.2026 14:42:27 CEST | Press release
Vislink to Present at the Emerging Growth Conference on Wednesday, August 19, 2026
The Metals Company17.8.2026 14:30:00 CEST | Press release
NOAA Publishes Notice of Intent in the Federal Register to Prepare an Environmental Impact Statement for TMC USA’s USA-B Exploration License Application
Novo Nordisk A/S17.8.2026 14:21:04 CEST | Press release
Novo Nordisk A/S - share repurchase programme
Intuitive Machines, LLC17.8.2026 14:00:00 CEST | Press release
Intuitive Machines Selected for Multi-Satellite Communications Infrastructure Program
Evaxion17.8.2026 14:00:00 CEST | Press release
Evaxion expands and refocuses R&D pipeline with EVX-05, an AI-designed off-the-shelf brain cancer vaccine program
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom